Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry

BMC Gastroenterology

Research Article

Rostislav Vyzula¹  Jiri Tomasek¹  Tomas Buchler²  Lubomir Slavicek³  Jana Prausova⁴  Bohuslav Melichar⁵  Jindrich Finek⁶  Zbynek Bortlicek⁷  Ladislav Dusek⁷  Tomas Pavlik⁷  Ondrej Majek⁷ 

[1] Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic;Department of Oncology and First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic;Department of Oncology, Hospital Jihlava, Jihlava, Czech Republic;Department of Oncology, Motol Hospital and Charles University, Prague, Czech Republic;Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic;Department of Oncology, University Hospital Pilsen, Pilsen, Czech Republic;Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic;

关键词: Anti-angiogenic therapy;    Chemotherapy;    Elderly patients;    Overall survival;    Progression-free survival;   

DOI  :  10.1186/1471-230X-14-53

 received in 2013-12-12, accepted in 2014-03-19,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundPatients aged 65 years and older represent the majority of patients with metastatic colorectal cancer (mCRC). However, this patient population is often underrepresented in clinical trials and probably undertreated in the clinical practice.MethodsWe have analysed the outcomes of 3,187 mCRC patients treated with first-line bevacizumab based on data from the Czech national registry of mCRC patients aiming to compare the treatment efficacy and safety according to the age categories.ResultsIn total, 2,126 (66.7%), 932 (29.2%), and 129 (4.0%) patients were aged <65 years, 65 to 75 years, and 75+ years, respectively. Median progression-free survival (PFS) was 11.4, 11.3, and 11.8 months for patients aged <65 years, 65 to 75 years, and 75+ years, respectively (p = 0.94). Median overall survival (OS) was 26.9, 27.5, and 25.1 months for patients aged <65 years, 65 to 75 years, and 75+ years, respectively (p = 0.73). Using multivariable Cox model for both PFS and OS, the patient age was not significantly associated with either PFS or OS. No increase in bevacizumab-related toxicity was observed among the elderly mCRC patients with the exception of hypertension, which was observed in 71 (3.3%), 34 (3.6%), and 10 (7.8%) patients aged <65 years, 65 to 75 years, and 75+ years, respectively.ConclusionsThe results of the present study suggest similar outcome in terms of OS and PFS with bevacizumab-containing therapy in elderly mCRC patients fit for chemotherapy combined with targeted therapy compared to younger patients. Thus, chronological age should not be considered to represent a limitation in prescribing bevacizumab-containing therapy in mCRC patients.

【 授权许可】

Unknown   
© Slavicek et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.